Show news: from last 30 days (default), 60 days, 90 days, last visit or all

Recombinant human erythropoietins: risk of severe cutaneous adverse reactions

24th October 2017

MHRA has informed healthcare professionals of the very rare risk of severe cutaneous reactions in patients treated with any recombinant human erythropoietin (r-HuEPO). The product information is being updated.

click here to view